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Association of Metabolic Surgery With Major Adverse 
Cardiovascular Outcomes in Patients With Type 2 
Diabetes and Obesity
In this observational retrospective study, 2287 patients with 
obesity (BMI ≥30 ) and type 2 diabetes who underwent meta-
bolic surgery within the Cleveland Clinic Health System, were 
matched 1:5 to nonsurgical patients with diabetes and obesity.
The primary end point was the incident of extended major 
adverse cardiovascular events (MACE, composite of 6 out-
comes), defined a first all-cause mortality, coronary artery 
events, cerebrovascular events, heart failure, nephropathy and 
atrial fibrillation. Secondary outcome included 3-component 
MACE (myocardial infarction, ischemic stroke and mortality). 
The median follow-up duration was 3.9 years. At the end of the 
study period, 385 (30.8%) patients in the surgical group and 
3243 (44.7%) patients in the nonsurgical group experienced a 
primary end point (hazard ratio, HR 0.61, 95% CI, 0.55 – 0.69). 
All secondary putcomes showed significantly differences in 
favor of metabolic surgery. All-cause mortality occurred in 112 
patients in the metabolic surgery group and 1111 patients in 
the nonsurgical group (HR = 0.59, 95%CI, 0.48-0.72). Meta-
bolic surgery was also associated with a significant reduction 
of HbA1c (mean difference between groups 1.1%), and use 
of noninsulin diabetes medication, insulin antihypertensive 
medications and lipid lower therapies. In the 90 days after 
metabolic surgery, complications included bleeding requiring 
transfusion (n=68, 3.0%), pulmonary adverse events (n=58, 
2.5%), venous thromboembolism (n=4, 0.2%), cardiac events 
(n=17, 0.7%), and renal failure requiring dialysis (n=4, 0.2%) 
(Aminlan A et al, JAMA 2019;322:1271-1282).
Comparative efficacy, safety, and cardiovascular outcomes 
with once-weekly subcutaneous semaglutide in the treatment 
of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
Semaglutide has 94% amino acid sequence homology with 
native GLP-1 and is currently approved by the FDA and EMA 
for the treatment of type 2 diabetes. 
The SUSTAIN (Semaglutide Unabated Sustainability in 
Treatment of Type 2 Diabetes) clinical trial program included 
7 randomised control trials involving more than 8000 patients 
with type 2 diabetes. Comparators were placebo (SUSTAIN 1,5 
and 6), sitagliptin (SUSTAIN 2), exenatide extended release 
(SUSTAIN 3), insulin glargine (SUSTAIN 4), and dulaglutide 
(SUSTAIN 7). Primary end points for SUSTAIN 1-5 and 7 
were changes to HbA1c from baseline to the end of treatment. 
In SUSTAIN 6, which included patients at high risk of CV 
disease, primary end point was time to first occurrence of 
major adverse CV event (3-point MACE) compared to placebo 
as add-on therapy. Across SUSTAIN 1-5 and 7, mean HbA1c 
decreased by 1.2-1.5% vs 0.1-0.4% with placebo and 0.5-
1.4% with sitagliptin, exenatide and insulin glargine. Across 
the SUSTAIN trials, semaglutide consistently demonstrated 
significantly greater body weight reduction vs. all compara-
tors. In SUSTAIN 6, the primary outcome of CV death and 
non-fatal or strolled occurred in 108 pf 1648 patients in the 
semaglutide group vs. 146 of 1659 patients in the placebo 
group (HR 0.74, CI=0.58-0.95; p<0.001 for non-inferiority). 
Overall, semaglutide demonstrated greater glycaemic ef-
ficacy combined with greater weight than comparator therapy. 
The safety profile was similar to other GLP-1RAs. In the 
SUSTAIN 6, semaglutide lowered the risk of adverse CV 
outcomes compared to placebo. (Aroda VR et al. Diabetes 
Metabolism, 2019;45:409-418).
Oral Semaglutide Versus Empagliflozin in Patients  
With Type 2 Diabetes Uncontrolled on Metformin:  
The PIONEER 2 Trial
In this randomized, open-label 52-week trial, patients with 
type 2 diabetes uncontrolled on metformin were randomized 
1:1 to once daily oral semaglutide 14 mg (n=412) or empa-
gliflozin 25 mg (n=410) for 52 weeks with a further 5 weeks 
follow-up. The primary end point was change in HbA1c from 
baseline to week 52. The confirmatory secondary end point 
was change in body weight (kg) from baseline to week 52. 
Oral semaglutide provided superior reduction in HbA1c 
vs. empagliflozin (-1.4% vs. -0.9%, p <0.0001). More patients 
achieved the predefined HbA1c targets of HbA1c <7% with 
oral semaglutide compared to empagliflozin without severe or 
symptomatic hypoglycemia. Fasting plasma glucose was equally 
reduced in both groups. At the end of the trial, a significantly 
greater reduction in body weight was achieved with oral sema-
glutide (-44.7 kg vs, -3.8 kg, p=0.0114). The overall number 
of adverse events were similar, and most events were mild to 
moderate (Rodbard H et al, Diabetes Care 2019;42:2272-2281).
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Efficacy, Safety, and Tolerability of Oral Semaglutide Versus 
Placebo Added to Insulin With or Without Metformin in 
Patients With Type 2 Diabetes: The PIONEER 8 Trial
Patients with type 2 diabetes uncontrolled on insulin (basal, 
basal-bolus, or premixed) with or without metformin were 
randomized to oral semaglutide 3 mg (n=148) 7 mg (n=182), 
or 14 mg (n=181) or to placebo (n=184) in a 52-week double-
blind trial.
The primary end point was change in HbA1c and confirma-
tory end point was change in body weight, from baseline to 
week 52.
Compared to placebo, HbA1c reductions were superior 
for all doses or oral semaglutide, with estimated difference 
of –0.5% (p <0.0001). The observed proportions of patients 
achieving HbA1c <7% and ≤6.5% were greater with semaglu-
tide, without hypoglycemia. Changes from baseline in FPG 
and 7-point SMBG means were statistically greater with oral 
semaglutide than placebo. The body weight reductions were 
superior for all doses of oral semaglutide (-0.9 kg, - 2.0 kg, -3.3 
kg for the 3-, 47-, and 14-mg doses, respectively). Gastrointes-
tinal disorders occurred most frequently in the oral semaglutide 
group (Zinman B et al, Diabetes Care 219;42:2262-2271).
SGLT2 inhibitors for the prevention of kidney failure  
in patients with type 2 diabetes: a systematic review  
and meta-analysis
In this systematic review and meta-analysis of randomised, 
controlled, cardiovascular or kidney outcome trials of SGLT2 
inhibitors (SGLT2i), the effects of this class medication on 
major kidney outcomes in people with type 2 diabetes was 
assessed. From 2085 records, four studies met the inclusion 
criteria, assessing three SGLT2 inhibitors: empagliflozin 
(EMPA-REG OUTCOME), canagliflozin (CANVAS Program 
and CREDENCE), and dapagliflozin (DECLARE-TIMI 58). 
From a total of 38723 participants, 252 required dialysis 
or transplantation or died of kidney disease, 335 developed 
end-sage kidney disease, and 943 had acute kidney injury, 
SGLT2 inhibitors substantially reduced the risk of dialysis, 
transplantation, or death due to kidney disease (RR=0.67, 
95% CI 0.52-0.86, p=0.0019). SGLT2i also reduced end-stage 
kidney disease (RR=0.65, p <0.0001), and acute kidney injury 
(RR=0.75, p <0.0001). These benefits were present across all 
eGFR subgroups, including for participants with a baseline 
eGFR=30-45 mL/min per 1.72 m² (Neuen B et al, Lancet 
Diabetes Endocrinol 2019;7:845-854).
Efficacy and safety of once-weekly semaglutide versus 
daily canagliflozin as add-on to metformin in patients 
with type 2 diabetes (SUSTAIN 8): a double-blind, phase 
3b, randomised controlled trial
In this double-blind randomised controlled trial, patients 
with uncontrolled type diabetes (hbA1c= 7-10.5% ) on stable 
daily metformin therapy, were assigned (1:1) to subcutaneous 
semaglutide 1.0 mg once weekly (n=394) or oral canagliflozin 
300 mg once daily (n=394). The primary endpoint was change 
in HbA1c from baseline to week 52, and the confirmatory 
secondary endpoint was change in body weight.
Patients receiving semaglutide had significantly greater 
reductions in HbA1c (-0.49%, p<0.0001) and in body weight 
(-1.06 kg, p=0.0029). Gastrointestinal disorders, mainly nausea, 
were the most frequent adverse events with semaglutide, oc-
curring in 47% of the semaglutide group; whereas infections, 
mainly urinary tract, occurred more often with canagliflozin 
(35% of the treated patients). Premature discontinuation due 
to adverse events was 10% (n=38) in the semaglutide and 
5% (n=20) in the canagliflozin group (Lingvay I et al, Lancet 
Diabetes Endocrinol 2019;7:834-844).
Cardiovascular, mortality, and kidney outcomes 
with GLP-1 receptor agonists in patients with type 
2 diabetes: a systematic review and meta-analysis of 
cardiovascular outcome trials
The meta-analysis summarizes the available evidence of 
the cardiovascular trials of GLP-1 receptor agonists, despite 
the differences in structure and duaration of acrions.
Of the 27 publications, seven trials with a total of 56004 
participants were examined: ELIXA (lixisenatide), LEADER 
(liraglutide), SUSTAIN-6 (semaglutide), EXSCEL ( exenatide), 
HARMONY (ablbiglutide), REWIND (dulaglutide), and PI-
IONEER 6 (oral semaglutide). These trials were characterized 
by a wide variability in the inclusion criteria and the median 
follow-up period. The proportion of patients with established 
cardiovascular disease at baseline ranged from 100% in ELIXA 
and HARMONY to 31% in REWIND. Kidney function was 
similar across trials with median eGFR ranging from 75-80 
mL/min per m². The estimated median follow-up was 3.2 years 
(1.3 in PIONEER to 5.4 in REWIND).
Overall, GLP-1RA significantly reduced MACE by 12% 
(HR=0.85, 95% CI 0.82- 0.94, p<0.001) with no statistically 
significant heterogeneity across the subgroups examined. 
HRs were 0.88 (95% CI 0.81-0.96, p=0.003) for death from 
cardiovascular causes, 0.84 (0.76-0.93, p<0.001) for fatal or 
non-fatal stroke and 0.91(0.84-1.00, p=0.0443) for fatal or 
non-fatal myocardial infarction. All-cause mortality was re-
duced by 12 % (p=0.001), hospitalization for heart failure by 
9% (p=0.028) and kidney-related outcome by 17% (p<0.001), 
mainly due to the reduction of urinary albumin excretion. No 
increase in risk of severer hypoglycemia, pancreatic adverse 
effects or thyroid cancer was observed.
Overall, GLP-1 receptor agonists were characterized as 
cardioprotective drugs (Κristemsen S et al, Lancet Diabetes 
Endocrinol 2019;7:776-785).
